🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

John Tamaresis

ORCID: 0000-0002-9868-2366
MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial”.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Nature Medicine(2021)10.1038/s41591-021-01436-0
N/A
4.8DataRank · unranked
582 citations

Shabnum Patel, Lori Muffly, Nasheed Hossain, Jean Oak, John H. Baird +44 more

CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study

The Lancet(2024)10.1016/s0140-6736(24)00746-3
N/A
1.4DataRank · unranked
60 citations

John H. Baird, Anne Marijn Kramer, Hrishikesh K. Srinagesh, Shabnum Patel, Annie Kathleen Brown +43 more

Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD

Blood Advances(2023)10.1182/bloodadvances.2023011625
N/A
0.906DataRank · unranked
31 citations

Anna Pavlova, Robert Lowsky, Lori Muffly, Parveen Shiraz, Sally Arai +17 more

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Blood(2025)10.1182/blood.2024026446
N/A
0.900DataRank · unranked
39 citations

Anna Pavlova, Alejandro Villar‐Prados, Cameron S. Bader, Bryan J. Xie, Lori Muffly +23 more

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy

Nature Medicine(2022)10.1038/s41591-022-01960-7
N/A
0.828DataRank · unranked
248 citations

Jay Y. Spiegel, Bita Sahaf, Meena Malipatlolla, Zachary Ehlinger, Sreevidya Kurra +25 more

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy

Blood Advances(2021)10.1182/bloodadvances.2021004716
N/A
0.659DataRank · unranked
80 citations

Juliana Craig, John H. Baird, Jay Y. Spiegel, Lori Muffly, James L. Zehnder +16 more

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Journal of Clinical Oncology(2024)10.1200/jco.23.02786
N/A
0.650DataRank · unranked
75 citations

Jay Y. Spiegel, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin +27 more

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias

Research Square(2025)10.21203/rs.3.rs-7746241/v1
N/A
0.104DataRank · unranked
1 citations

Mark P. Hamilton, Nick Phillips, Troy Noordenbos, Jan Boegeholz, Takeshi Sugio +32 more

CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity

Blood Advances(2024)10.1182/bloodadvances.2024012637
N/A
0DataRank · unranked
24 citations

Erin Craig, Cesar Gentille Sanchez, Alain Mina, John Tamaresis, Nadia Kirmani +27 more

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

Blood Advances(2021)10.1182/bloodadvances.2020002732
N/A
0DataRank · unranked
194 citations

David J. Epstein, John Tamaresis, Zachary Ehlinger, Jay Y. Spiegel, Juliana Craig +18 more

A Composite Endpoint for Treatment Benefit According to Patient Preference

Statistics in Biopharmaceutical Research(2022)10.1080/19466315.2022.2085783
N/A
0DataRank · unranked
8 citations

Qian Zhao, Jiying Zou, Shiyan Yan, John Tamaresis, Lorene M. Nelson +4 more